A pill that beat a pill, which is the part that matters
For most people living with relapsing multiple sclerosis, the strongest treatments come as an infusion in a clinic or a regular injection. On September 1, 2026, Novartis said its experimental once-daily pill, remibrutinib, cut how often relapses happened better than teriflunomide, one of the oral MS drugs people already take at home.
That is the headline worth holding onto. A convenient pill that works as well as or better than an existing convenient pill is a real step, because the barrier for many patients is not just whether a drug works, it is whether they can actually stick with it week after week.
There is a catch, and it is an unusual one. Novartis announced that the trials worked but did not say by how much.
What Novartis actually reported
The results come from two Phase III trials, REMODEL-1 and REMODEL-2, running the same design in parallel so a win in both is harder to write off as luck. Together they enrolled roughly 2,000 adults with relapsing MS around the world. Everyone was randomly assigned to remibrutinib or to teriflunomide, an approved MS pill, so the comparison is against a real treatment rather than a sugar pill.
The main question the trials asked was the annualized relapse rate, meaning how many flare-ups a patient has in a year. Both trials hit that goal: remibrutinib lowered the relapse rate by a statistically significant margin compared with teriflunomide. Novartis also said the drug beat teriflunomide on all the key secondary measures inside each trial, including the number of active lesions seen on MRI brain scans.
| Finding | Plain-English meaning |
|---|---|
| Primary goal met in both REMODEL-1 and REMODEL-2 | The relapse benefit showed up twice, in two separate trials, not just once. |
| Fewer relapses vs teriflunomide, not vs placebo | It was tested against a real approved pill and still came out ahead. |
| Superior on all key secondary endpoints, including MRI lesions | Brain scans backed up the relapse result, which is what neurologists look for. |
| ~2,000 patients enrolled worldwide | A large trial, so the result is less likely to be a fluke of a small sample. |
| No liver safety signal, no cases meeting the standard liver-injury threshold | The one thing that has sunk similar drugs did not show up here. |
| Exact percentages not yet released | The size of the benefit is still unknown until the full data are presented. |
Why the liver line is the quiet headline
Remibrutinib belongs to a family of drugs called BTK inhibitors, which target immune cells believed to drive the nerve damage in MS. On paper the class has looked promising for years. In practice its biggest problem has not been whether the drugs work, it has been the liver. Several competing BTK programs in MS have run into liver-safety trouble that forced pauses, restrictions, or extra monitoring.
So when Novartis specifically stated that remibrutinib showed no liver safety signal, and that no patient met the usual laboratory threshold used to flag serious drug-related liver injury, that was not routine box-ticking. For this particular drug class, a clean liver readout is close to the whole ballgame. It is the difference between a therapy neurologists can prescribe simply and one that comes wrapped in blood tests and warnings.
The disability result is smaller than it sounds
Relapses are the visible part of MS. The part patients fear more is disability that creeps in and does not go away. Here the news is genuine but modest, and it is worth being precise about.
Novartis reported a positive trend on three-month confirmed disability progression, and a result it called nominally significant on six-month confirmed disability progression, but only when the two trials were pooled together in a preplanned combined analysis. In plain terms: there is an early hint the drug may slow disability, but it did not clear the bar cleanly inside each individual trial, and “nominally significant” is softer than the standard the primary goal had to meet. It is a reason for cautious optimism, not proof that the drug protects against long-term disability.
What is missing, and why you should notice
- The actual numbers. A topline release that says “significant” without a single percentage is asking to be taken partly on trust. Until the effect sizes are published, nobody outside Novartis can judge whether the relapse benefit is large or merely real.
- The comparison people really want. Teriflunomide is a reasonable yardstick, but it is not the most powerful MS therapy available. Beating it is meaningful, yet it does not tell us how remibrutinib stacks up against the strong infusions and injections many patients are already on.
- Long-term safety. A clean liver signal over a trial is encouraging, but BTK inhibitors act broadly on the immune system, and infection and other risks over years of use can only be judged with time.
- Durability of the disability effect. A pooled, nominally significant hint at six months is a starting point, not a track record. Whether that translates into people staying on their feet longer is a question the follow-up data will have to answer.
Novartis says it will present the full late-breaking data at a medical meeting later in 2026 and plans to file for approval with regulators globally. Both of those are the right next steps. Neither has happened yet.
What to do with this if MS affects you or someone you love
- Do not expect it at the pharmacy soon. It is not approved anywhere. A regulatory filing is the start of a long review, not the finish line.
- Bring it to your next neurology visit as a question, not a demand. Ask how an oral BTK inhibitor might fit your type of MS and your current treatment, and what the full data show once they are out.
- Keep taking your current therapy. A promising trial for a different drug is never a reason to stop the treatment that is working for you now. Any change is a conversation with your neurologist.
- Watch for the full data. When the actual relapse and disability numbers are published, that is the moment to judge how big this really is. A press release that withholds the figures is a headline, not the evidence.
The honest read is that this is good news held slightly out of focus. Two large trials pointing the same way, against a real comparator, with the class’s usual liver problem apparently absent, is the kind of result that earns attention. Just remember that “it worked” and “here is exactly how well it worked” are two different claims, and so far Novartis has only made the first one.
Related Coverage
Sources:
- novartis.com, “Novartis remibrutinib significantly reduces relapse rates in Phase III RMS trials” (https://www.novartis.com/news/media-releases/novartis-remibrutinib-high-efficacy-oral-btk-inhibitor-significantly-reduces-relapse-rates-and-shows-favorable-safety-profile-phase-iii-rms-trials)
- pharmashots.com, “Novartis Reports P-III (REMODEL-1/-2) Trial Data on Remibrutinib for Relapsing Multiple Sclerosis” (https://pharmashots.com/35512/novartis-reports-p-iii-remodel-1-2-trial-data-on-remibrutinib-for-relapsing-multiple-sclerosis)
- rttnews.com, “Novartis’ Phase 3 REMODEL Trials For Remibrutinib In Multiple Sclerosis Meet Primary Endpoint” (https://www.rttnews.com/3687467/novartis-phase-3-remodel-trials-for-remibrutinib-in-multiple-sclerosis-meet-primary-endpoint.aspx)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.